Caution, this is an AI generated summary based on literature. This may have errors, see here for more.
Please share your feedback with us.
mir3609: MIR3609, a microRNA, has been identified as a potential biomarker for locally advanced breast cancer due to its downregulated expression [PMC9818474]. It contributes to the immune response against breast cancer by inhibiting the PD-L1 immune checkpoint, potentially enhancing the effectiveness of immune-mediated tumor cell clearance [PMC7527443]. MIR3609 can also bind to the 3′ UTR region of PD-L1 mRNA and reduce its expression, which may sensitize breast cancer cells to the chemotherapeutic agent doxorubicin [PMC9713762]. While the downregulation of MIR3609 and its precursor in cells with inhibited kalirin–GEF1 has been observed, it implies a regulatory mechanism that may lead to the upregulation of their target genes, which are involved in processes such as cell morphogenesis and neuron differentiation [PMC8017594, PMC9727336]. Moreover, the upregulation of MIR3609 has been associated with increased sensitivity of breast cancer cells to Adriamycin, which is synonymous with doxorubicin [PMC9727336].
mRNA interactions
total
Genome locations
Gene Ontology annotations
Ancestor Chart
Loading ontology ancestors...
Failed to load QuickGO Ancestor chart
Sequence
Sequence features are shown above as colored rectangles.
Zoom in and click to view details, or
Reset
